… of lytic bacteriophages (phages) to design a trial using inhaled single phage therapy, informed
by our experiences with compassionate use cases. This study investigated phage therapy …

… safety and efficacy of this treatment, this includes and is not limited to the Cystic Fibrosis
Bacteriophage Study at Yale (CYPHY, NCT04684641) and the Children’s Hospital at Westmead …

… The phages used in this study were provided by AmpliPhi Australia Pty Ltd. (Brookvale, …
This research was partly funded by the Cystic Fibrosis Trust, UK and the Strategic Research …

… study (Cystic Fibrosis Bacteriophage Study at Yale CYPHY, … Yale Phage Therapy 01 (YPT-01),
a nebulized single-phage therapy [104]. However, although phage therapy in the study …

… examining safety/efficacy of phage therapy in CF patients (CYPHY; … cystic fibrosis (CF) was
referred to the Center for Phage Biology & Therapy at Yale for consideration of bacteriophage …

… more effective phage product. The first successful treatment using engineered phages was in
2019 in a patient with cystic fibrosis … This case used the bacteriophage recombineering and …

… antipseudomonal phages used in the Cystic Fibrosis Bacteriophage Study at Yale (CYPHY, …
We propagated the CYPHY phages and stored them at 10 9 PFU/mL in conditions in which …

… patient with cystic fibrosis underwent two rounds of 2 phage cocktails given via … of phage
therapy in adult patients with cystic fibrosis who had chronic P. aeruginosa-induced pulmonary …

… as preclinical studies that demonstrated phage efficacy against … CYstic Fibrosis bacterioPHage
Study at Yale (CYPHY) is a phase 2 study evaluating the use of an inhaled single phage …

… In this study, phage treatment was well tolerated, and no phage … activity of phage therapy
in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a …